Assembly, Allergan deal

Assembly granted Allergan exclusive, worldwide rights to preclinical candidates ABI-M201, which is in development for ulcerative colitis; and ABI-M301, which is in development for Crohn’s disease. The deal also includes two undisclosed compounds in discovery to treat irritable bowel syndrome (IBS). Assembly will have an option to co-promote the programs in the U.S. and China. ABI-M201 and ABI-M301 are microbiome therapeutics based on Assembly's colon-targeted Gemicel drug delivery platform. The deal is expected to close this quarter...